Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S)-pseudotyped viruses are commonly used for quantifying antiviral drugs and neutralizing antibodies. Here, we describe the development of a hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) pseudovirion, which is a non-replicating SARS-CoV-2 virus-like particle composed of viral structural proteins (S, M, N, and E) and an RNA genome derived from a fast-expressing alphaviral vector. We validated Ha-CoV-2 for rapid quantification of neutralization antibodies, antiviral drugs, and viral variants. In addition, as a proof of concept, we used Ha-CoV-2 to quantify the neutralizing antibodies from an infected and vaccinated individual and found that the one-dose vaccination with Moderna mRNA-1273 greatly increased the anti-serum titer by approximately 6-fold. The post-vaccination serum can neutralize all nine variants tested. These results demonstrate that Ha-CoV-2 can be used as a robust platform for the rapid quantification of neutralizing antibodies against SARS-CoV-2 and its emerging variants.
【저자키워드】 COVID-19, neutralizing antibody, SARS-CoV-2, coronavirus, mRNA vaccine, antiviral drug, SARS-CoV-2 variants, pseudovirus, lentivirus, Ha-CoV-2, alphavirus, 【초록키워드】 vaccination, Neutralizing antibodies, mRNA-1273, antiviral drugs, variant, variants, Spike protein, serum, neutralization antibodies, Viral variants, structural protein, quantification, platform, Moderna, acute respiratory syndrome, RNA genome, vaccinated individual, neutralize, robust, tested, virus, composed, addition, nine, can be used, 【제목키워드】 development, quantification, Neutralization antibody,